Aegerion 2% convertibles now convertible for Novelion stock

New York, Nov. 29 – Aegerion Pharmaceuticals, Inc. said its 2% convertible senior notes due 2019 are now convertible into 24.9083 shares of Novelion Therapeutics Inc. common stock, according to an 8-K filing with the Securities and Exchange Commission.

The change, effective Tuesday, follows completion of the acquisition of Aegerion by QLT Inc. The combined company has been renamed Novelion.

Conversions of the Aegerion notes can be settled in cash, stock or a combination, at the company’s option.

Aegerion is a specialty pharmaceutical company based in Cambridge, Mass. QLT is a Vancouver, B.C.-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.